IMMX (Immix Biopharma, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IMMX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-29 | Gabriel S Morris | CFO, President | A | — | — |
| 2026-05-29 | Ilya M Rachman | CEO and Chairman | A | — | — |
| 2026-05-29 | NANCY T CHANG | Director | A | — | — |
| 2026-05-29 | Carey Ng | Director | A | — | — |
| 2026-05-29 | Magda Marquet | Director | A | — | — |
| 2026-05-29 | Helen C. Adams | Director | A | — | — |
| 2026-05-29 | JANE BUCHAN | Director | A | — | — |
| 2026-05-29 | Jason Hsu | Director | A | — | — |
| 2026-05-29 | Yekaterina Chudnovsky | Director | A | — | — |
| 2025-12-11 | NANCY T CHANG | Director | A | — | — |
| 2025-12-10 | Gabriel S Morris | CFO | MIXED | — | — |
| 2025-12-10 | Ilya M Rachman | CEO and Chairman | Buy | — | — |
| 2025-09-17 | Ilya M Rachman | CEO and Chairman | Buy | — | — |
| 2025-09-17 | Gabriel S Morris | CFO | Buy | — | — |
| 2025-06-23 | Gabriel S Morris | CFO | A | — | — |
| 2025-06-23 | Carey Ng | Director | A | — | — |
| 2025-06-23 | Ilya M Rachman | CEO and Chairman | A | — | — |
| 2025-06-23 | Yekaterina Chudnovsky | Director | A | — | — |
| 2025-06-23 | Jason Hsu | Director | A | — | — |
| 2025-06-23 | Magda Marquet | Director | A | — | — |
| 2025-06-23 | JANE BUCHAN | Director | A | — | — |
| 2025-06-23 | Helen C. Adams | Director | A | — | — |
| 2025-06-20 | Gabriel S Morris | CFO | Buy | — | — |
| 2025-06-20 | Ilya M Rachman | CEO and Chairman | Buy | — | — |
| 2024-12-26 | Jason Hsu | Director | Buy | — | — |
| 2024-08-26 | Jason Hsu | Director | Buy | — | — |
| 2024-08-19 | Carey Ng | Director | Buy | — | — |
| 2024-07-31 | Jason Hsu | Director | Buy | — | — |
| 2024-06-21 | JANE BUCHAN | Director | A | — | — |
| 2024-06-21 | Ilya M Rachman | CEO and Chairman | A | — | — |
| 2024-06-21 | Gabriel S Morris | CFO | A | — | — |
| 2024-06-21 | Yekaterina Chudnovsky | Director | A | — | — |
| 2024-06-21 | Carey Ng | Director | A | — | — |
| 2024-06-21 | Helen C. Adams | Director | A | — | — |
| 2024-06-21 | Jason Hsu | Director | A | — | — |
| 2024-06-21 | Magda Marquet | Director | A | — | — |
| 2024-06-10 | Ilya M Rachman | CEO and Chairman | Buy | — | — |
| 2024-06-10 | Gabriel S Morris | CFO | Buy | — | — |
| 2024-06-05 | Gabriel S Morris | CFO | Buy | — | — |
| 2024-06-05 | Ilya M Rachman | CEO and Chairman | Buy | — | — |
| 2024-05-20 | Carey Ng | Director | A | — | — |
| 2024-05-20 | Ilya M Rachman | CEO and Chairman | A | — | — |
| 2024-05-20 | JANE BUCHAN | Director | A | — | — |
| 2024-05-20 | Helen C. Adams | Director | A | — | — |
| 2024-05-20 | Jason Hsu | Director | A | — | — |
| 2024-05-20 | Gabriel S Morris | CFO | A | — | — |
| 2024-05-20 | Magda Marquet | Director | A | — | — |
| 2024-05-14 | Gabriel S Morris | CFO | Buy | — | — |
| 2024-05-14 | Ilya M Rachman | CEO and Chairman | Buy | — | — |
| 2023-12-12 | Jason Hsu | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 3,247,326 | — |
| — | CEO and Chairman | 1,141,683 | — |
| — | Director | 1,051,471 | — |
| — | Director | 949,250 | — |
| — | Director | 925,130 | — |
| — | Scientific Co-Founder | 902,200 | — |
| — | 10%+ Owner | 899,800 | — |
| — | CFO, President | 718,273 | — |
| — | Director | 181,004 | — |
| — | Director | 72,342 | — |
| — | Director | 28,705 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IMMX quote page; the site-wide leaderboard is on the insider transactions hub.